Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Regains Nasdaq Compliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics has regained compliance with a Nasdaq rule that its stock meet a minimum $1 share price and will remain listed on the exchange, it announced after the close of the market on Thursday.

The company said that it has received notice from Nasdaq that it will continue being listed on the Nasdaq Capital Market under ticker symbol "ROSGD" through Aug. 3, then revert back to ticker symbol "ROSG" on Aug. 4.

Nasdaq rules stipulate that in order to be traded on its Capital Market, a company's stock must have a closing bid price of at least $1 for 10 consecutive trading days. Rosetta Genomics had been given until Aug. 8 to satisfy the condition.

Earlier this month, the Israeli microRNA-based molecular diagnostics company underwent a one-for-four reverse stock split to satisfy the requirement.

At the close of the market on Thursday, shares of Rosetta Genomics were down 6 percent at $1.50.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.